1-Myristoyl-2-Hydroxy-sn-Glyc-3-Phosphatidylethanolamine

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 1-Myristoyl-2-Hydroxy-sn-Glyc-3-Phosphatidylethanolamine
• 英文别名: 2-azaniumylethyl (2-hydroxy-3-tetradecanoyloxypropyl) phosphate
• 化学式: C₁₉H₄₀NO₇P
• 分子量: 425.5
• InChiKey: RPXHXZNGZBHSMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  28
• 可旋转键数：
  21
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  133
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Microbial consortia
  申请人：Siolta Therapeutics, Inc.

  公开号：US11369644B2

  公开（公告）日：2022-06-28

  Provided herein are microbial strains isolated de novo. In some instances, the bacterial strains include genera, species, and/or strains of Lactobacillus johnsonii, Lactobacillus crispatus, Faecalibacterium prausnitzii, Akkermansia muciniphila, Bifidobacterium longum, and/or Bifidobacterium longum infantis strains. These bacterial strains can be used in the treatment of dysbiosis, inflammation, and other disorders.

  本文提供了从新分离的微生物菌株。在某些情况下，这些细菌菌株包括约翰逊乳杆菌属、脆片乳杆菌属、普鲁士尼茨粪杆菌属、黏液粘杆菌属、长双歧杆菌属和/或婴儿长双歧杆菌属的属、种和/或菌株。这些细菌菌株可用于治疗菌群失调、炎症和其他疾病。
• MICROBIAL CONSORTIA
  申请人：Siolta Therapeutics, Inc.

  公开号：EP3773645A1

  公开（公告）日：2021-02-17
• Chemosensory Receptor Ligand-Based Therapies
  申请人：Brown Martin R.

  公开号：US20130303466A1

  公开（公告）日：2013-11-14

  Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
• [EN] MICROBIAL CONSORTIA<br/>[FR] CONSORTIA MICROBIENS
  申请人：SIOLTA THERAPEUTICS INC

  公开号：WO2019199895A1

  公开（公告）日：2019-10-17

  Provided herein are microbial strains isolated de novo. In some instances, the bacterial strains include genera, species, and/or strains of Lactobacillus johnsonii, Lactobacillus crispatus, Faecalibacterium prausnitzii, Akkermansia muciniphila, Bifidobacterium longum, and/or Bifidobacterium longum infantis strains. These bacterial strains can be used in the treatment of dysbiosis, inflammation, and other disorders.